NeilMed Pharmaceuticals Receives FDA Warning Letter Over Glycerin Identity Testing Failures at Santa Rosa Facility

Glycerin identity testing gaps at NeilMed Pharmaceuticals Inc. have drawn a formal FDA Warning Letter, exposing a component qualification breakdown that QA directors across OTC drug manufacturing should read as a direct audit prompt. The letter, issued May 26, 2023, followed an inspection of the Santa Rosa, California facility conducted November 28 through December 2, 2022.

FDA investigators cited violations of 21 CFR 211.84(d)(1) and 211.84(d)(2), finding that NeilMed failed to perform identity testing on each incoming shipment of glycerin lots using the USP identification method capable of detecting diethylene glycol (DEG) and ethylene glycol (EG). The firm also released one glycerin lot from an unqualified supplier, relying solely on the manufacturer's certificate of analysis, to manufacture multiple batches of its Clear Canal product. Both practices fall outside CGMP requirements for finished pharmaceuticals under 21 CFR Parts 210 and 211.

The DEG and EG contamination risk in glycerin and propylene glycol is not theoretical. FDA's warning letter references lethal poisoning incidents in humans worldwide linked to these impurities, and the agency's guidance on testing high-risk drug components sets explicit expectations for per-shipment, per-lot identity testing. NeilMed's December 15, 2022 response committed to revising glycerin material specifications, but FDA found the corrective action inadequate on two counts: identity testing had not been performed on glycerin lots already in inventory, and the firm had not addressed whether distributed, in-expiry drug products containing those lots would be evaluated.

For incoming component programs, the enforcement signal is precise. Supplier COAs do not substitute for independent identity testing on high-risk excipients, and supplier qualification must be validated at appropriate intervals rather than assumed from documentation alone. FDA's guidance document on Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for DEG and EG remains the operative reference for establishing compliant specifications.

NeilMed's path to resolution will require a comprehensive, independent review of its material system, a remediation scope that typically intersects CAPA documentation, supplier qualification records, and retrospective lot disposition decisions for distributed product still within expiry.

Source: U.S. Food and Drug Administration Warning Letter (FEI 3002998723), Division of Pharmaceutical Quality Operations IV, via FDA.gov, May 26, 2023.